Back

IFN and IFN mimetics prevent IFN-I-mediated TB susceptibility by regulating iron metabolism and lipid peroxidation

Araveti, P. B.; Yabaji, S. M.; Arifin, M. Z.; Lata, S.; Alekseyev, Y. O.; Gimelbrant, A. A.; Bishai, W. R.; Zhernovkov, V.; Rukhlenko, O. S.; Kholodenko, B. N.; Kramnik, I.

2026-07-07 immunology
10.64898/2026.07.01.735930 bioRxiv
Show abstract

Type I interferons (IFN-I) and IFN{gamma} exert divergent effects during tuberculosis, but the mechanisms that determine whether macrophage activation promotes host defense or inflammatory pathology remain incompletely understood. Here, we dissect the interplay between IFN-I and IFN{gamma} in macrophage activation using genetically susceptible B6.Sst1S macrophages. We show that, during tumor necrosis factor (TNF) stimulation, susceptible macrophages enter a persistent pathological activation state (pPAS) characterized by sustained lipid peroxidation and super-induction of IFN-I responses. This pathological state is maintained by autocrine IFN-I signaling. In contrast, IFN{gamma} priming prevents pPAS development by enhancing macrophage resilience to oxidative stress, in part through regulation of iron metabolism and induction of ferritin expression. Computational cell state transition assessment and regulation (cSTAR) analysis identified pathways and small molecules predicted to promote the transition of susceptible macrophages toward an IFN{gamma}-induced, Mtb-resistant state. Consistent with these predictions, the CDK4/6 inhibitor trilaciclib reduced lipid peroxidation by regulating iron metabolism, whereas retinoic acid signaling enhanced GPX4 expression and lipid biosynthesis programs. Combined CDK4/6 inhibition and retinoic acid receptor activation efficiently prevented the pathological activation state. Together, these findings delineate a mechanism of IFN-I/IFN{gamma} crosstalk during macrophage activation and identify pharmacologic strategies to prevent IFN-I-dominant, lipid peroxidation-driven macrophage pathology.

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

1
The Journal of Immunology
166 papers in training set
Top 0.1%
12.7%
2
PLOS Pathogens
820 papers in training set
Top 1%
10.8%
3
eLife
5828 papers in training set
Top 17%
6.6%
4
Cell Reports
1498 papers in training set
Top 5%
6.6%
5
Nature Communications
5641 papers in training set
Top 26%
6.2%
6
Proceedings of the National Academy of Sciences
2444 papers in training set
Top 8%
6.2%
7
Frontiers in Immunology
638 papers in training set
Top 3%
4.8%
50% of probability mass above
8
Journal of Experimental Medicine
119 papers in training set
Top 0.8%
3.2%
9
Immunity
67 papers in training set
Top 0.7%
2.7%
10
mBio
833 papers in training set
Top 6%
2.6%
11
Nature Immunology
79 papers in training set
Top 1%
2.1%
12
JCI Insight
277 papers in training set
Top 4%
1.9%
13
Science Advances
1243 papers in training set
Top 20%
1.7%
14
Communications Biology
993 papers in training set
Top 14%
1.7%
15
Journal of Clinical Investigation
179 papers in training set
Top 3%
1.5%
16
PLOS Biology
486 papers in training set
Top 6%
1.5%
17
The Journal of Infectious Diseases
202 papers in training set
Top 3%
1.1%
18
Cell Chemical Biology
94 papers in training set
Top 1%
1.1%
19
Science Signaling
65 papers in training set
Top 1%
1.1%
20
eBioMedicine
183 papers in training set
Top 5%
1.0%
21
ACS Infectious Diseases
82 papers in training set
Top 1%
1.0%
22
The EMBO Journal
309 papers in training set
Top 6%
1.0%
23
Infection and Immunity
120 papers in training set
Top 2%
1.0%
24
Scientific Reports
3612 papers in training set
Top 72%
0.9%
25
ImmunoHorizons
24 papers in training set
Top 0.5%
0.9%
26
PLOS ONE
5266 papers in training set
Top 62%
0.8%
27
Journal of Biological Chemistry
690 papers in training set
Top 10%
0.8%
28
iScience
1154 papers in training set
Top 36%
0.8%
29
Science Translational Medicine
127 papers in training set
Top 4%
0.8%
30
EMBO Molecular Medicine
95 papers in training set
Top 3%
0.8%